Product
Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
A Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) (WSK-V101C) in Booster Vaccination in Healthy Population 18 Years Old of Age and AboveStatus: Not yet recruiting, Estimated PCD: 2024-06-30